EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more
TLDR
These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.Abstract:
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6 months (or improvement not seen atread more
Citations
More filters
Journal ArticleDOI
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh,Daniel E. Furst,Aseem Bharat,Jeffrey R. Curtis,Arthur Kavanaugh,Joel M. Kremer,Larry W. Moreland,James O'Dell,Kevin L. Winthrop,Timothy Beukelman,S. Louis Bridges,W. Winn Chatham,Harold E. Paulus,Maria E. Suarez-Almazor,Claire Bombardier,Maxime Dougados,Dinesh Khanna,Charles M. King,Amye L. Leong,Eric L. Matteson,John T. Schousboe,Eileen Moynihan,Karen S. Kolba,Archana Jain,Elizabeth R. Volkmann,Harsh Agrawal,Sangmee Bae,Amy S. Mudano,Nivedita M. Patkar,Kenneth G. Saag +29 more
TL;DR: The 2012 ACR RA recommendations were developed by two expert panels: a non-voting working group and Core Expert Panel of clinicians and methodologists responsible for the selection of the relevant topic areas to be considered, the systematic literature review, and the evidence synthesis.
Journal ArticleDOI
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Désirée van der Heijde,Sofia Ramiro,Robert Landewé,Xenofon Baraliakos,Filip Van den Bosch,Alexandre Sepriano,Alexandre Sepriano,Andrea Regel,Adrian Ciurea,Hanne Dagfinrud,Maxime Dougados,Maxime Dougados,Floris A. van Gaalen,Pál Géher,Irene E. van der Horst-Bruinsma,Robert D. Inman,Merryn Jongkees,Uta Kiltz,Tore K Kvien,Pedro Machado,Helena Marzo-Ortega,Anna Molto,Anna Molto,Victoria Navarro-Compán,Salih Ozgocmen,Fernando Pimentel-Santos,John D. Reveille,Martin Rudwaleit,Martin Rudwaleit,J. Sieper,Percival D. Sampaio-Barros,Dieter Wiek,Jürgen Braun +32 more
TL;DR: The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA and three overarching principles and 13 recommendations deal with surgery and spinal fractures.
Journal ArticleDOI
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Josef S Smolen,Ferdinand C. Breedveld,Gerd R Burmester,Vivian P. Bykerk,Maxime Dougados,Paul Emery,Tore K Kvien,M Victoria Navarro-Compán,Susan Oliver,Monika Schoels,Marieke Scholte-Voshaar,Tanja Stamm,Michaela Stoffer,Tsutomu Takeuchi,Daniel Aletaha,Jose Louis Andreu,Martin Aringer,Martin J. Bergman,Neil Betteridge,H. Bijlsma,Harald Burkhardt,Mario H. Cardiel,Bernard Combe,Patrick Durez,João Eurico Fonseca,A. Gibofsky,Juan J. Gomez-Reino,Winfried Graninger,Pekka Hannonen,Boulos Haraoui,Marios Kouloumas,Robert Landewé,Emilio Martín-Mola,Peter Nash,Mikkel Østergaard,Andrew J. K. Östör,Pam Richards,T. Sokka-Isler,Carter Thorne,Athanasios G. Tzioufas,Ronald F van Vollenhoven,Martinus de Wit,Désirée van der Heijde +42 more
TL;DR: The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.
Journal ArticleDOI
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.
Tomasz J. Guzik,Tomasz J. Guzik,Saidi A Mohiddin,Anthony Dimarco,Vimal Patel,K Savvatis,Federica M. Marelli-Berg,Meena S. Madhur,Maciej Tomaszewski,Pasquale Maffia,Pasquale Maffia,Fulvio D'Acquisto,Stuart A. Nicklin,Ali J. Marian,Ryszard Nosalski,Ryszard Nosalski,Eleanor Murray,Bartłomiej Guzik,Colin Berry,Rhian M. Touyz,Reinhold Kreutz,Dao Wen Wang,David Bhella,Orlando Sagliocco,Filippo Crea,E. Thomson,Iain B. McInnes +26 more
TL;DR: While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis, Hence, patients should not discontinue their use.
Journal ArticleDOI
Diagnosis and Management of Rheumatoid Arthritis: A Review.
Daniel Aletaha,Josef S Smolen +1 more
TL;DR: A treat-to-target strategy aimed at reducing disease activity by at least 50% within 3 months and achieving remission or low disease activity within 6 months, with sequential drug treatment if needed, can prevent RA-related disability.
References
More filters
Journal ArticleDOI
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial
Joel M. Kremer,Mark C. Genovese,Grant W. Cannon,Jacques Caldwell,John J. Cush,Daniel E. Furst,Michael E. Luggen,E.C. Keystone,Michael H. Weisman,William M. Bensen,Jeffrey L. Kaine,Eric Ruderman,Patricia Coleman,David Curtis,Elliot J. Kopp,Seth M. Kantor,Jonathan Waltuck,Herbert B. Lindsley,Joseph A. Markenson,Vibeke Strand,Bruce Crawford,Indra Fernando,Karen Simpson,Joan M. Bathon +23 more
TL;DR: In this article, the authors evaluated the efficacy and safety of leflunomide versus placebo when added to ongoing, stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis.
Journal ArticleDOI
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
Rene Westhovens,Manuel Robles,Antonio Carlos Ximenes,Savithree Nayiager,Jürgen Wollenhaupt,Patrick Durez,Juan J. Gomez-Reino,Walter Grassi,Boulous Haraoui,William Shergy,Sung-Hwan Park,Harry K. Genant,Charles Peterfy,Jean-Claude Becker,A Covucci,Roy Helfrick,Joan M. Bathon +16 more
TL;DR: In a methotrexate-naive population with early RA and poor prognostic factors, the combination of abatacept and methotRexate provided significantly better clinical and radiographic efficacy compared with methot Rexate alone and had a comparable, favourable safety profile.
Journal ArticleDOI
Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?
Angel Gonzalez,H. Maradit Kremers,Cynthia S. Crowson,Karla V. Ballman,Veronique L. Roger,Steven J. Jacobsen,William M. O'Fallon,Sherine E. Gabriel +7 more
TL;DR: Differences in the overall impact of traditionalCV risk factors suggest that strategies to prevent CV disease and mortality focused solely on controlling traditional CV risk factors may be relatively less beneficial in RA subjects than in the general population.
Journal ArticleDOI
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
Anja Strangfeld,Maria Eveslage,Matthias F. Schneider,H. J. Bergerhausen,T. Klopsch,A. Zink,Joachim Listing +6 more
TL;DR: The crude rates of serious infections in patients treated with TNF inhibitors declined over the first 3 years of observation, driven by a risk reduction through decreasing glucocorticoid doses and improvement in function.
Reference EntryDOI
Biologics for rheumatoid arthritis: an overview of Cochrane reviews
Jasvinder A. Singh,Robin Christensen,George A. Wells,Maria E. Suarez-Almazor,Rachelle Buchbinder,Maria A. Lopez-Olivo,Elizabeth Tanjong Ghogomu,Peter Tugwell +7 more
TL;DR: Anakinra seemed less efficacious than etanercept, adalimumab and rituximab and etanerscept and seemed to cause fewer withdrawals due to adverse events than ad alimumab, anakinra and infliximab, however there is a lack of head-to-head comparison studies.
Related Papers (5)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh,Kenneth G. Saag,S. Louis Bridges,Elie A. Akl,Raveendhara R. Bannuru,Matthew C. Sullivan,Elizaveta E. Vaysbrot,Christine McNaughton,Mikala C. Osani,Robert H. Shmerling,Jeffrey R. Curtis,Daniel E. Furst,Deborah Parks,Arthur Kavanaugh,James R. O'Dell,Charles H. King,Amye Leong,Eric L. Matteson,John T. Schousboe,Barbara E. Drevlow,Seth Ginsberg,James Grober,E. William St. Clair,Elizabeth A. Tindall,Amy S. Miller,Timothy E. McAlindon +25 more
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Daniel Aletaha,Tuhina Neogi,Alan J. Silman,Julia Funovits,David T. Felson,Clifton O. Bingham,Neal S. Birnbaum,Gerd Burmester,Vivian P. Bykerk,Marc D. Cohen,Bernard Combe,Karen H. Costenbader,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Johanna M. W. Hazes,Kathryn Hobbs,Tom W J Huizinga,Arthur Kavanaugh,Jonathan Kay,Tore K Kvien,Timothy J. Laing,Philip J. Mease,Henri A Ménard,Larry W. Moreland,Raymond L. Naden,Theodore Pincus,Josef S Smolen,Ewa Stanislawska-Biernat,Deborah P M Symmons,Paul P. Tak,Katherine S. Upchurch,Jiří Vencovský,Frederick Wolfe,Gillian A. Hawker +34 more
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S Smolen,Daniel Aletaha,J. Bijlsma,Ferdinand C. Breedveld,Dimitrios T. Boumpas,Gerd R Burmester,Bernard Combe,Maurizio Cutolo,Maarten de Wit,Maxime Dougados,Paul Emery,A. Gibofsky,Juan J. Gomez-Reino,Boulos Haraoui,Joachim Kalden,Edward C. Keystone,Tore K Kvien,Iain B. McInnes,Emilio Martín-Mola,Carlomaurizio Montecucco,Monika Schoels,Désirée van der Heijde +21 more
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh,Daniel E. Furst,Aseem Bharat,Jeffrey R. Curtis,Arthur Kavanaugh,Joel M. Kremer,Larry W. Moreland,James O'Dell,Kevin L. Winthrop,Timothy Beukelman,S. Louis Bridges,W. Winn Chatham,Harold E. Paulus,Maria E. Suarez-Almazor,Claire Bombardier,Maxime Dougados,Dinesh Khanna,Charles M. King,Amye L. Leong,Eric L. Matteson,John T. Schousboe,Eileen Moynihan,Karen S. Kolba,Archana Jain,Elizabeth R. Volkmann,Harsh Agrawal,Sangmee Bae,Amy S. Mudano,Nivedita M. Patkar,Kenneth G. Saag +29 more